Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C4H9NO2S.ClH |
Molecular Weight | 171.646 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)[C@@H](N)CS
InChI
InChIKey=WHOHXJZQBJXAKL-DFWYDOINSA-N
InChI=1S/C4H9NO2S.ClH/c1-7-4(6)3(5)2-8;/h3,8H,2,5H2,1H3;1H/t3-;/m0./s1
Mecysteine is used as a mucolytic in respiratory disorders associated with productive cough. Mecysteine is known as a mucolytic
agent, it breaks down mucus. It works by breaking some
of the chemical bonds between the molecules in mucus. It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days. Mecysteine has also been given by inhalation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Mucus glycoproteins Sources: https://www.ncbi.nlm.nih.gov/pubmed/6185664 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
|||
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
|||
Primary | VISCLAIR Approved UseVisclair is used together with other medicines to help in the treatment of conditions in which thick mucus is a problem. e.g. chronic obstructive pulmonary disease, sinusitis (inflamed nasal tubes), secretory otitis and in the symptomatic relief of cough with sputum or phlegm. |
PubMed
Title | Date | PubMed |
---|---|---|
Water-soluble organosulfur compounds of garlic inhibit fatty acid and triglyceride syntheses in cultured rat hepatocytes. | 2001 Apr |
|
The formation of malodorous dimethyl oligosulphides in treated groundwater: the role of biofilms and potential precursors. | 2001 May |
|
lcd from Streptococcus anginosus encodes a C-S lyase with alpha,beta-elimination activity that degrades L-cysteine. | 2002 Dec |
|
Mild and highly chemoselective oxidation of thioethers mediated by Sc(OTf)3. | 2003 Feb 6 |
|
Redox inversion of helicity in propeller-shaped molecules derived from s-methyl cysteine and methioninol. | 2003 Mar 6 |
|
Synthesis and biological activity of photoactivatable N-ras peptides and proteins. | 2003 Oct 22 |
|
Effect of five cysteine-containing compounds on three lipogenic enzymes in Balb/cA mice consuming a high saturated fat diet. | 2004 Sep |
|
Immobilized metal affinity beads for ferritin adsorption. | 2005 |
|
Cysteine methyl ester modified glassy carbon spheres for removal of toxic heavy metals from aqueous media. | 2005 Aug 7 |
|
Synthesis of pipecolic acid-based spiro bicyclic lactam scaffolds as beta-turn mimics. | 2005 Jul 22 |
|
Maillard reaction products derived from thiol compounds as inhibitors of enzymatic browning of fruits and vegetables: the structure-activity relationship. | 2005 Jun |
|
The role of hydrogen bonding in the selectivity of L-cysteine methyl ester (CYSM) and L-cysteine ethyl ester (CYSE) for chloride ion. | 2005 Mar |
|
Kinetics and mechanistic studies of the hydrolysis of diisocyanate-derived bis-thiocarbamates of cysteine methyl ester. | 2006 Mar |
|
Mathematical modelling and simulation of adsorption processes at spherical microparticles. | 2006 Mar 13 |
|
Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. | 2006 Nov |
|
Observation of cysteine thiolate and -S...H-O intermolecular hydrogen bond. | 2006 Nov 23 |
|
Electrospray ionization and triple quadrupole tandem mass spectrometry study of some biologically relevant homo- and heterodimeric cadmium thiolate conjugates. | 2006 Oct |
|
One-electron reduction of S-nitrosothiols in aqueous medium. | 2006 Oct 15 |
|
Removal of toxic metal-ion pollutants from water by using chemically modified carbon powders. | 2006 Oct 20 |
|
Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities. | 2007 |
|
Reduction of vanadium(V) to vanadium(IV) by NADPH, and vanadium(IV) to vanadium(III) by cysteine methyl ester in the presence of biologically relevant ligands. | 2007 Aug |
|
Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. | 2007 Jul-Aug |
|
Facile discrimination of aldose enantiomers by reversed-phase HPLC. | 2007 Jun |
|
Antiinflammatory and antifibrogenic effects of s-ethyl cysteine and s-methyl cysteine in the kidney of diabetic mice. | 2007 May |
|
Protective and alleviative effects from 4 cysteine-containing compounds on ethanol-induced acute liver injury through suppression of oxidation and inflammation. | 2007 Sep |
|
Synthesis, docking and anti-tumor activity of beta-L-1,3-thiazolidine pyrimidine nucleoside analogues. | 2007 Sep |
|
A viable synthesis of N-methyl cysteine. | 2008 |
|
The uptake and fate of vanadyl ion in ascidian blood cells and a detailed hypothesis for the mechanism and location of biological vanadium reduction. A visible and X-ray absorption spectroscopic study. | 2008 Apr |
|
Radioprotectant and radiosensitizer effects on sterility of gamma-irradiated bone. | 2008 Aug |
|
Characterization, reactivity and photosensitizing properties of the triplet excited state of alpha-lapachone. | 2008 Nov 28 |
|
Equilibrium and kinetic investigations of the interaction of model platinum(II) complex with DNA constituents in reference to the antitumour activity: complex-formation reactions of [Pd(N,N-diethylethylenediamine)(H2O)2]2+ with ligands of biological significance and displacement reactions of DNA constituents. | 2009 |
|
Optical activity and chiral memory of thiol-capped CdTe nanocrystals. | 2009 Aug 5 |
|
Aurintricarboxylic acid inhibits influenza virus neuraminidase. | 2009 Feb |
|
In vitro glutathione conjugation of methyl iodide in rat, rabbit, and human blood and tissues. | 2009 May |
|
Inhibitory effects of cysteine and cysteine derivatives on germination of sporangiospores and hyphal growth of different Zygomycetes. | 2009 Sep |
|
Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates. | 2009 Sep 21 |
|
A new method for the detection and characterization of alpha-lipoic acid mixed disulphides. | 2010 Apr |
|
Redetermination of di-μ-sulfido-bis-{[(2R)-2-acet-oxy-2-amino-ethane-1-thiol-ato-κN,S]oxidomolybdenum(V)}. | 2010 Apr 24 |
|
Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. | 2010 Aug |
|
hi2-1, a QTL which improves harvest index, earliness and alters metabolite accumulation of processing tomatoes. | 2010 Nov |
|
Gold nanoparticles conjugated to benzoylmercaptoacetyltriglycine and L-cysteine methylester. | 2010 Oct 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://en.pharmacodia.com/web/drug/1_12336.html
Curator's Comment: Mecysteine has also been given by inhalation.
It is given orally in a usual dose of 200 mg three times daily before meals reduced to 200 mg twice daily after 6 weeks. A rapid clinical effect can be achieved by giving 200 mg four times daily for the first 2 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6185664
The effects of L-cysteine methyl ester (Mecysteine) on behavior of mucus glycoproteins in canine tracheal secretory cells were investigated histologically and histochemically. Low concentrations (10(-7) and 10(-6)M) of L-cysteine methyl ester produced, as histological changes, decreases in the total goblet cell number and the thickness of the acini of submucosal glands, and an increase in the acinar inner diameter. On the other hand, L-cysteine methyl ester at 10(-5) and 10(-4)M produced an increase in the thickness of the acini and a slight decrease in the acinar inner diameter.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C017507
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
33RG619160
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
100000086184
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
18598-63-5
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
161611
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
m7126
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
5714-80-7
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
29144
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
SUB03110MIG
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
DTXSID9046520
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
235828
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
242-435-0
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
227-208-6
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD